These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 36090967)
1. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma. Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y Front Immunol; 2022; 13():965469. PubMed ID: 36090967 [TBL] [Abstract][Full Text] [Related]
2. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X Front Immunol; 2021; 12():725223. PubMed ID: 34484235 [TBL] [Abstract][Full Text] [Related]
3. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer. Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J Front Immunol; 2021; 12():791924. PubMed ID: 34975891 [TBL] [Abstract][Full Text] [Related]
4. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076 [No Abstract] [Full Text] [Related]
5. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer. Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785 [TBL] [Abstract][Full Text] [Related]
6. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma. Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161 [No Abstract] [Full Text] [Related]
7. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer. Wu T; Li S; Yu C; Wu Y; Long H Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer. Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S Front Immunol; 2023; 14():1326509. PubMed ID: 38130721 [TBL] [Abstract][Full Text] [Related]
9. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Lu H; Wu J; Liang L; Wang X; Cai H Front Immunol; 2022; 13():803355. PubMed ID: 35154117 [TBL] [Abstract][Full Text] [Related]
10. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma. Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J Front Immunol; 2022; 13():964393. PubMed ID: 36211344 [TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
12. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer. Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764 [TBL] [Abstract][Full Text] [Related]
13. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer. Ma X; Wei X; Yang G; Li S; Liu R Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625 [TBL] [Abstract][Full Text] [Related]
14. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer. Xiao Z; Cai Z; Deng D; Tong S; Zu X Front Immunol; 2022; 13():1000321. PubMed ID: 36211349 [TBL] [Abstract][Full Text] [Related]
15. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536 [TBL] [Abstract][Full Text] [Related]
16. GATA3 Predicts the Tumor Microenvironment Phenotypes and Molecular Subtypes for Bladder Carcinoma. Zhang Q; Qi T; Long Y; Li X; Yao Y; Wu Q; Zou A; Qthmane B; Liu P Front Surg; 2022; 9():860663. PubMed ID: 35647011 [TBL] [Abstract][Full Text] [Related]
17. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer. Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664 [TBL] [Abstract][Full Text] [Related]
18. Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465 [TBL] [Abstract][Full Text] [Related]
20. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer. Tan Z; Fu S; Zuo J; Wang J; Wang H Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]